A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.

PLoS One · 2023 · PMC10468037 · PMID 37647320

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Due to a relatively small sample size compared to the overall population the predictions based on dichotomized scores are only borderline significant in the phase III RCC trial, and not significant in the individual small phase II trials.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.